

**Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest
and a Waiver under 18 U.S.C. §208(b)(3)**

Ronald Bukowski, M.D.

Committee: Oncologic Drugs Advisory Committee

Meeting Date: September 6-7, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to (1) New Drug Application (NDA) 21-874, proposed trade name Genasense (oblimersen sodium) Injection, sponsored by Genta Inc., for use in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia who are refractory to or have relapsed after therapy with fludarabine; (2) NDA 20-287, Fragmin (dalteparin sodium injection), sponsored by Pfizer, Inc., for the extended treatment of symptomatic venous thromboembolism (VTE) (proximal deep vein thrombosis (DVT) and/or pulmonary embolism (PE)) to reduce the recurrence of VTE in patients with cancer; and (3) NDA 21-660, Abraxane (paclitaxel protein-bound particles for injectable suspension)(albumin-bound), sponsored by Abraxis BioScience, Inc., including trial design issues for adjuvant treatment of node-positive breast cancer, I am eligible to receive a waiver under 18 U.S.C. §208(b)(3).

Type of Interest	Nature	Magnitude
Unrelated Consulting	2 Competitors for issues 1 and 2	Less than \$5,001 per year per firm
Unrelated Consulting	Sponsor of issue 2 and competitor for issues 2 and 3	Less than \$5,001 per year
Unrelated Speaker's Bureau	Competitor for issues 1 and 3	Less than \$5,001 per year

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests, the waiver is not valid.

/s/
Signature

8/17/06
Date